Ginkgo Bioworks (DNA) Stock
Platform for engineering microbes across pharmaceutical and industrial use. Here's the price, business snapshot, and what's worth knowing about Ginkgo Bioworks in August 2026.
Ginkgo Bioworks (ticker: DNA) is a synthetic-biology company that designs and engineers microorganisms for customers across industries, from pharmaceuticals to agriculture and industrial chemicals. The business operates a cell‑programming platform and offers foundry services, partnerships and licensing to generate revenue. With a market capitalisation around $737.9m, Ginkgo is a small‑cap company that has invested heavily in R&D, capacity and acquisitions to expand its platform — a strategy that has weighed on near‑term profitability. Potential upside comes from scalable services, recurring revenues from partnerships and novel product opportunities, but the stock can be volatile: progress depends on scientific success, customer adoption, regulatory outcomes and capital markets. Investors should note the company’s development stage, potential for further fundraising and biotech sector risks. This information is educational only and not personal investment advice; consider your risk tolerance and seek professional advice before investing.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest selling Ginkgo Bioworks stock due to a lower expected value than its current price.
Financial Health
Ginkgo Bioworks is showing solid cash flow and revenue, with a strong profit margin indicating good operational efficiency.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Platform potential
Ginkgo’s cell‑programming platform could unlock recurring services and licensing revenue as customers scale, though commercial outcomes and timing can vary.
Partnership momentum
Collaborations and agreements can accelerate revenue and validation, but returns depend on execution and may take time to materialise.
Science and regulation
Scientific progress and regulatory approvals shape long‑term value; investors should expect developmental and policy uncertainties.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
